OXM can inhibit food intake, elevate metabolic rate, and cause weight loss when administered peripherally in humans, sparking interest in the use of OXM or related glucagon-GLP-1 receptor co-agonists as a potential therapy for obesity (Wynne et al. 2005, 2006). This evidence concerns the gene GLP1R and Obesity.